November 13th, 2026FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBCThe FDA approved durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer.Read more
November 7th, 2026VET3-TGI Generates Responses in Checkpoint Inhibitor–Refractory Cutaneous CancersVET3-TGI produced responses in injected and non-injected lesions without dose-limiting toxicities in the phase 1/1b STEALTH-001 trial.Read more
November 6th, 2026Canakinumab Reduces Nodule Size in High-Risk Lung PrecancersIL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.Read more
November 6th, 2026VGX-3100 Elicits Regression and Clearance in HPV-16/18–Associated Cervical HSILsVGX-3100 met its composite primary end point in the phase 3 HPV-303CHN trial, supporting a nonsurgical treatment approach for HPV-16/18–associated cervical HSIL.Read more
November 6th, 2026EVX-01 Plus Pembrolizumab Yields Neoantigen-Specific T-Cell Responses in Advanced MelanomaEVX-01 plus pembrolizumab generated sustained neoantigen-specific T-cell responses in advanced melanoma.Read more